Bristol Myers Squibb Company
NEWS
BMS is looking to hire “several hundred employees over the next few years,” all working to ensure the production of both their clinical and commercial cell therapies.
The companies have announced their intent to appeal the decision.
The U.S. Food and Drug Administration (FDA) has several solid PDUFA dates in the middle of February. Here’s a look.
It was a busy week for clinical trial announcements and news. Here’s a look.
Eric Poma, chief executive and scientific officer for Molecular Templates, touted the partnership with BMS and its strong oncology franchise.
The company’s head of drug development, Samit Hirawat, told analysts in a conference call last week that the decision was about working with the best drugs, particularly in a crowded field like BCMA.
Bristol Myers Squibb and Exelixis announced new analysis from the Phase III CheckMate -9ER clinical trial.
Bristol Myers picked up the therapy when it acquired Celgene in 2019 for $74 billion.
It was a busy week for clinical trial updates. Here’s a look.
JOBS
IN THE PRESS